Nexstar Pharmaceuticals, Inc.
Records under this name other than patents Nexstar Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Nexstar Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,600,568 | Safety Vent Valve Formerly held In force · High confidence | In force | High confidence | |
| US 6,770,290 | Amphotericin B liposome preparation Term ended Ended no later than Aug 3, 2021 · USPTO record | Term ended | Ended no later than Aug 3, 2021 | USPTO record |
| US 6,261,783 | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction Formerly held Term ended Term ended Aug 11, 2020 · USPTO record | Term ended | Term ended Aug 11, 2020 | USPTO record |
| US 7,258,980 | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligands Formerly held Term ended Term ended Jun 20, 2020 · USPTO record | Term ended | Term ended Jun 20, 2020 | USPTO record |
| US 6,426,335 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes Formerly held Term ended Ended no later than Mar 13, 2020 · USPTO record | Term ended | Ended no later than Mar 13, 2020 | USPTO record |
| US 6,051,698 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes Formerly held Term ended Term ended Feb 20, 2020 · USPTO record | Term ended | Term ended Feb 20, 2020 | USPTO record |
| US 6,177,555 | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction Formerly held Term ended Term ended Nov 23, 2019 · USPTO record | Term ended | Term ended Nov 23, 2019 | USPTO record |
| US 6,448,392 | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use Term ended Ended no later than Sep 10, 2019 · USPTO record | Term ended | Ended no later than Sep 10, 2019 | USPTO record |
| US 6,171,795 | Nucleic acid ligands to CD40ligand Formerly held Term ended Term ended Jul 29, 2019 · USPTO record | Term ended | Term ended Jul 29, 2019 | USPTO record |
| US 6,506,887 | Conditional-selex Formerly held Term ended Term ended Jul 29, 2019 · USPTO record | Term ended | Term ended Jul 29, 2019 | USPTO record |